Orbimed Advisors LLC Has $22.43 Million Stake in Intercept Pharmaceuticals Inc (ICPT)

Orbimed Advisors LLC lowered its holdings in shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 54.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 386,380 shares of the biopharmaceutical company’s stock after selling 470,174 shares during the period. Orbimed Advisors LLC owned approximately 1.54% of Intercept Pharmaceuticals worth $22,425,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Public Employees Retirement Association of Colorado lifted its holdings in shares of Intercept Pharmaceuticals by 1.1% in the second quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 43 shares in the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Intercept Pharmaceuticals by 1.8% in the second quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock valued at $416,000 after purchasing an additional 62 shares in the last quarter. WFG Advisors LP increased its position in shares of Intercept Pharmaceuticals by 16.4% during the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 125 shares during the last quarter. Utah Retirement Systems increased its position in shares of Intercept Pharmaceuticals by 6.5% during the second quarter. Utah Retirement Systems now owns 3,300 shares of the biopharmaceutical company’s stock valued at $400,000 after acquiring an additional 200 shares during the last quarter. Finally, State of Wisconsin Investment Board increased its position in shares of Intercept Pharmaceuticals by 7.9% during the second quarter. State of Wisconsin Investment Board now owns 3,567 shares of the biopharmaceutical company’s stock valued at $432,000 after acquiring an additional 260 shares during the last quarter. 73.76% of the stock is owned by institutional investors and hedge funds.

ICPT has been the subject of a number of research analyst reports. Wells Fargo & Co reaffirmed an “outperform” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Cantor Fitzgerald reissued an “underweight” rating and issued a $69.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Jefferies Group reissued a “buy” rating and issued a $275.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Robert W. Baird reiterated an “outperform” rating and issued a $332.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $221.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Intercept Pharmaceuticals has an average rating of “Hold” and a consensus target price of $141.58.

Shares of Intercept Pharmaceuticals Inc (ICPT) traded up $56.35 on Tuesday, hitting $56.35. The stock had a trading volume of 1,907,200 shares, compared to its average volume of 617,379. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. Intercept Pharmaceuticals Inc has a 12-month low of $54.98 and a 12-month high of $135.59. The company has a market cap of $1,410.00, a PE ratio of -3.81 and a beta of -2.08.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) EPS for the quarter, topping analysts’ consensus estimates of ($3.48) by $0.59. The firm had revenue of $41.33 million for the quarter, compared to analysts’ expectations of $36.95 million. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The business’s revenue for the quarter was up 697.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($3.59) EPS. sell-side analysts forecast that Intercept Pharmaceuticals Inc will post -13.35 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.truebluetribune.com/2018/01/03/intercept-pharmaceuticals-inc-icpt-shares-sold-by-orbimed-advisors-llc.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply